Literature DB >> 24189477

Long-term outcome of 'super-responder' patients to cardiac resynchronization therapy.

Massimo Zecchin1, Alberto Proclemer, Silvia Magnani, Laura Vitali-Serdoz, Domenico Facchin, Daniele Muser, Andrea Nordio, Giulia Barbati, Ilaria Puggia, Gianfranco Sinagra, Alessandro Proclemer.   

Abstract

AIMS: To evaluate the long-term changes of clinical and echocardiographic parameters, the incidence of cardiac events and parameters associated with late cardiac events in 'super-responders' to cardiac resynchronization therapy (CRT) with [CRT defibrillator (CRT-D)] or without defibrillator back-up. METHODS AND
RESULTS: In all consecutive patients treated with CRT in two Italian centres (Trieste and Udine) with left ventricular ejection fraction (LVEF) ≤0.35 at implantation (Timp) and LVEF > 0.50 1 and/or 2 years (Tnorm) after implantation, the long-term outcome and the evolution of echocardiographic parameters were assessed; factors associated with a higher risk of cardiac events, defined as hospitalization or death for heart failure (HF), sudden death, or CRT-D appropriate interventions, were also analysed. Among the 259 patients evaluated, 62 (24%) had LVEF ≥ 0.50 at Tnorm (n = 44 with at 1 year, n = 18 at 2 years). During a mean follow-up of 68 ± 30 months, one cardiac death (for HF) and eight cardiovascular events (two hospitalization for HF and six appropriate CRT-D interventions) occurred. At the last echo evaluation (Tfup) performed 51 ± 26 months after Timp, LVEF was <0.50 in five patients (>0.45 in four of them). At univariable analysis, only LV end-systolic volume evaluated at Tfup was associated with a higher risk of cardiac events during follow-up.
CONCLUSION: In 'super-responders' to CRT long-term outcome is excellent. However, cardiac events, mainly CRT-D appropriate interventions, can occur despite the persistence of LVEF > 0.50. Early identification of these patients is still an unsolved issue.

Entities:  

Keywords:  Cardiac resynchronization therapy; Heart failure; Outcome; Super-responders

Mesh:

Year:  2013        PMID: 24189477     DOI: 10.1093/europace/eut339

Source DB:  PubMed          Journal:  Europace        ISSN: 1099-5129            Impact factor:   5.214


  9 in total

1.  Predictors and long-term outcome of super-responders to cardiac resynchronization therapy.

Authors:  Abdul Ghani; Peter Paul H M Delnoy; Ahmet Adiyaman; Jan Paul Ottervanger; Anand R Ramdat Misier; Jaap Jan J Smit; Arif Elvan
Journal:  Clin Cardiol       Date:  2017-03-14       Impact factor: 2.882

Review 2.  Heart Failure with Recovered EF and Heart Failure with Mid-Range EF: Current Recommendations and Controversies.

Authors:  Peter Unkovic; Anupam Basuray
Journal:  Curr Treat Options Cardiovasc Med       Date:  2018-04-03

Review 3.  Reverse remodeling in Dilated Cardiomyopathy: Insights and future perspectives.

Authors:  M Merlo; T Caiffa; M Gobbo; L Adamo; G Sinagra
Journal:  Int J Cardiol Heart Vasc       Date:  2018-03-08

4.  Does 'super-responder' patients to cardiac resynchronization therapy still have indications for neuro-hormonal antagonists? Evidence from long-term follow-up in a single center.

Authors:  Yi-Ran Hu; Wei Hua; Han Jin; Min Gu; Xiao-Han Fan; Hong-Xia Niu; Li-Gang Ding; Jing Wang; Shu Zhang
Journal:  J Geriatr Cardiol       Date:  2019-03       Impact factor: 3.327

5.  Causes-of-death analysis of patients with cardiac resynchronization therapy: an analysis of the CeRtiTuDe cohort study.

Authors:  Eloi Marijon; Christophe Leclercq; Kumar Narayanan; Serge Boveda; Didier Klug; Jonathan Lacaze-Gadonneix; Pascal Defaye; Sophie Jacob; Olivier Piot; Jean-Claude Deharo; Marie-Cecile Perier; Genevieve Mulak; Jean-Sylvain Hermida; Paul Milliez; Daniel Gras; Olivier Cesari; Françoise Hidden-Lucet; Frederic Anselme; Philippe Chevalier; Philippe Maury; Nicolas Sadoul; Pierre Bordachar; Serge Cazeau; Michel Chauvin; Jean-Philippe Empana; Xavier Jouven; Jean-Claude Daubert; Jean-Yves Le Heuzey
Journal:  Eur Heart J       Date:  2015-09-01       Impact factor: 29.983

Review 6.  Importance of Implantable Cardioverter-Defibrillator Back-Up in Cardiac Resynchronization Therapy Recipients: A Systematic Review and Meta-Analysis.

Authors:  Sérgio Barra; Rui Providência; Anthony Tang; Patrick Heck; Munmohan Virdee; Sharad Agarwal
Journal:  J Am Heart Assoc       Date:  2015-11-06       Impact factor: 5.501

7.  Association of apical rocking with super-response to cardiac resynchronisation therapy.

Authors:  A Ghani; P P H M Delnoy; J J J Smit; J P Ottervanger; A R Ramdat Misier; A Adiyaman; A Elvan
Journal:  Neth Heart J       Date:  2016-01       Impact factor: 2.380

8.  Echocardiographic markers of dyssynchrony as predictors of super-response to cardiac resynchronisation therapy - a pilot study.

Authors:  V A Kuznetsov; A M Soldatova; J D Kasprzak; D V Krinochkin; N N Melnikov
Journal:  Cardiovasc Ultrasound       Date:  2018-10-02       Impact factor: 2.062

9.  Predictors of super-response to cardiac resynchronization therapy: the significance of heart failure medication, pre-implant left ventricular geometry and high percentage of biventricular pacing.

Authors:  Han Jin; Min Gu; Wei Hua; Xiao-Han Fan; Hong-Xia Niu; Li-Gang Ding; Jing Wang; Cong Xue; Shu Zhang
Journal:  J Geriatr Cardiol       Date:  2017-12       Impact factor: 3.327

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.